Recently, anti-proinflammatory cytokine therapies against interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-1 were introduced in inflammatory disease therapy, especially for rheumatoid arthritis [42]. Here, IL1B is linked to rheumatoid arthritis.